Idogen updates in connection with the Swedish Medical Products Agency's approval of phase 1/2a study
Anders Karlsson, CEO of Idogen AB, visited BioStock's studio in connection with the company receiving the Swedish Medicines Agency's approval of its clinical phase 1/2a study for IDO 8, a completely new type of cell therapy for patients with severe hemophilia A who have developed antibodies to its vital treatment with coagulation factor VIII. The purpose of IDO 8 is to create tolerance for and enable continued treatment with factor VIII.
The clinical study has been designed in close dialogue with leading specialists in coagulation disorders and regulatory authorities in the Nordic region with the aim of evaluating the safety of IDO 8 and following signals of treatment effect in patients.
In the interview with BioStock, Anders Karlsson talks about the company's planning for the start of the study.
The interview is available here https://www.biostock.se/2022/03/biostock-studio-idogen-far-godkant-for-fas-i-iia-studie-med-ido-8/
For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Phone: +46 70 918 00 10
Email: anders.karlsson@idogen.com
Certified Adviser:
Erik Penser Bank AB, Box 7405, 103 91 Stockholm
Phone: +46 (0)8-463 80 00
Email: certifiedadviser@penser.se
The information was submitted for publication, through the agency of the contact persons set out above, on 22 March 2022 at 12:16 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com